[HTML][HTML] How we treat primary central nervous system lymphoma
T Calimeri, S Steffanoni, F Gagliardi, A Chiara… - ESMO open, 2021 - Elsevier
Primary diffuse large B-cell (DLBCL) lymphoma of the central nervous system
(CNS)(PCNSL) is a new lymphoma entity, recognized by the 2017 WHO classification of …
(CNS)(PCNSL) is a new lymphoma entity, recognized by the 2017 WHO classification of …
Cold Kit Labeling: The Future of 68Ga Radiopharmaceuticals?
N Lepareur - Frontiers in Medicine, 2022 - frontiersin.org
Over the last couple of decades, gallium-68 (68Ga) has gained a formidable interest for PET
molecular imaging of various conditions, from cancer to infection, through cardiac …
molecular imaging of various conditions, from cancer to infection, through cardiac …
In vivo targeting of CXCR4—new horizons
M Schottelius, K Herrmann, C Lapa - Cancers, 2021 - mdpi.com
Simple Summary Beyond its pre-eminent role in the context of tumor cell growth as well as
metastasis, the CXC motif chemokine receptor 4 (CXCR4) is a key player in the …
metastasis, the CXC motif chemokine receptor 4 (CXCR4) is a key player in the …
CXCR4 PET/MRI for follow-up of gastric mucosa–associated lymphoid tissue lymphoma after first-line Helicobacter pylori eradication
ME Mayerhoefer, M Raderer, W Lamm… - Blood, The Journal …, 2022 - ashpublications.org
Posttreatment evaluation of gastric mucosa-associated lymphoid tissue (MALT) lymphoma
currently relies on esophagogastroduodenoscopy with histological assessment of biopsies …
currently relies on esophagogastroduodenoscopy with histological assessment of biopsies …
[HTML][HTML] Research progress of CXCR4-targeting radioligands for oncologic imaging
Y Wang, F Gao - Korean Journal of Radiology, 2023 - ncbi.nlm.nih.gov
CXC motif chemokine receptor 4 (CXCR4) plays a key role in various physiological
functions, such as immune processes and disease development, and can influence …
functions, such as immune processes and disease development, and can influence …
[HTML][HTML] CXCR4 PET imaging of mantle cell lymphoma using [68Ga] Pentixafor: comparison with [18F] FDG-PET
ME Mayerhoefer, M Raderer, W Lamm, V Pichler… - Theranostics, 2021 - ncbi.nlm.nih.gov
For PET imaging of mantle cell lymphoma (MCL),[18 F] FDG (2-deoxy-2-[18 F] fluoro-D-
glucose) is the currently recommended radiotracer, although uptake is variable and bone …
glucose) is the currently recommended radiotracer, although uptake is variable and bone …
The Role of [68Ga]Ga-Pentixafor PET/CT or PET/MRI in Lymphoma: A Systematic Review
D Albano, F Dondi, F Bertagna, G Treglia - Cancers, 2022 - mdpi.com
Simple Summary Preliminary evidence about the useful impact of [68Ga] Ga-Pentixafor
PET/CT or PET/MRI in lymphoma is available but reveals heterogeneous findings. The aim …
PET/CT or PET/MRI in lymphoma is available but reveals heterogeneous findings. The aim …
Advances in PET Imaging of the CXCR4 Receptor:[68Ga] Ga-PentixaFor
L Lindenberg, M Ahlman, F Lin, E Mena… - Seminars in Nuclear …, 2023 - Elsevier
[68 Ga] Ga-PentixaFor, a PET agent targeting CXCR4 is emerging as a versatile radiotracer
with promising applications in oncology, cardiology and inflammatory disease. Preclinical …
with promising applications in oncology, cardiology and inflammatory disease. Preclinical …
Development of a Rare Earth Nanoprobe Enables In Vivo Real-Time Detection of Sentinel Lymph Node Metastasis of Breast Cancer Using NIR-IIb Imaging
YY Zhu, L Song, YQ Zhang, WL Liu, WL Chen, WL Gao… - Cancer Research, 2023 - AACR
Sentinel lymph node (SLN) biopsy plays a critical role in axillary staging of breast cancer.
However, traditional SLN mapping does not accurately discern the presence or absence of …
However, traditional SLN mapping does not accurately discern the presence or absence of …
Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients
R Lewis, S Habringer, M Kircher, M Hefter, CA Peuker… - EJNMMI research, 2021 - Springer
Background The chemokine receptor CXCR4 is frequently overexpressed and associated
with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently …
with adverse prognosis in most hematopoietic malignancies and solid cancers. Recently …